Denosumab for Treatment of Hypercalcemia of Malignancy

CONTEXT: Hypercalcemia of malignancy (HCM) in patients with advanced cancer is often caused by excessive osteoclast-mediated bone resorption. Patients may not respond to or may relapse after iv bisphosphonate therapy. OBJECTIVE: We investigated whether denosumab, a potent inhibitor of osteoclast-med...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Hu, Mimi I., Glezerman, Ilya G., Leboulleux, Sophie, Insogna, Karl, Gucalp, Rasim, Misiorowski, Waldemar, Yu, Bennett, Zorsky, Paul, Tosi, Diego, Bessudo, Alberto, Jaccard, Arnaud, Tonini, Giuseppe, Ying, Wendy, Braun, Ada, Jain, Rajul K.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Endocrine Society 2014
Aiheet:
Endocrine Care
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4154084/
https://ncbi.nlm.nih.gov/pubmed/24915117
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2014-1001
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia